Sofix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sofix

What is Sofix? Identity and Pharmacological Classification

Property Description
Active ingredient Cefixime
Form Tablets, Capsules, Oral Suspension, Oral Liquid
Pharmacological class beta-Lactam Antibiotic / Third-Generation Cephalosporin
Common use Systemic treatment of Bacterial Infections
Origin Semisynthetic

Sofix is the commercial trade name for the prescription-only medicine containing the active substance Cefixime. This compound is a semisynthetic antibiotic (C16H15N5O7S2) classified as a third-generation cephalosporin, distinguishing it by its structural complexity and enhanced spectrum of activity. Cefixime is clinically recognized for its stability against common bacterial resistance mechanisms. The general purpose of this medication is to address and resolve bacterial infections.


Cefixime Forms, Mechanism, and General Purpose

Pharmacologically, Cefixime belongs to the overarching beta-lactam class, unified by its specific chemical structure and defined by its role as a potent broad-spectrum antibacterial agent. Its advanced classification ensures it is effective against a wider range of susceptible organisms than many older antibiotics. This efficacy is rooted in its bactericidal action, which causes the death of bacteria by interfering with the synthesis of the bacterial cell wall.

Cefixime is a single-ingredient product intended for oral intake. It is manufactured in various pharmaceutical preparations, including solid forms like tablets and capsules, alongside liquid formulations such as the oral suspension and oral liquid. The availability of these different forms is a key factor in ensuring flexible administration across diverse patient groups, notably the oral suspension form for pediatric patients.

What side effects are possible with Sofix?

Possible side effects and safety information

The safety profile of Sofix (Cefixime) reflects adverse reactions classified by frequency and the body system affected, as documented in official regulatory sources. The most frequently reported adverse reactions are related to the Gastrointestinal System.


Classification of Documented Adverse Reactions

Classification System-Organ Class Examples (from regulatory labeling)
Common / Very Common Gastrointestinal Disorders Diarrhea, loose stools, abdominal pain, nausea.
Uncommon / Less Common Nervous System Disorders Headache, dizziness.
Rare Hemic and Lymphatic System, Renal Disorders Thrombocytopenia, leukopenia, acute renal failure, hepatitis.

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but serious adverse reactions, which include Anaphylactic/Anaphylactoid Reactions and severe skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Treatment with Cefixime is also associated with the risk of developing Clostridium difficile-Associated Diarrhea (CDAD), which may occur during or after therapy has concluded.

Population-Specific Safety Notes are defined for certain patient groups. Safety and efficacy have not been established in infants under six months of age. Patients with renal impairment are noted to have a heightened risk of systemic adverse reactions, including potential neurotoxicity. Furthermore, the concurrent use of Cefixime with coumarin-type anticoagulants may be associated with an increase in prothrombin time, a high-level safety consequence explicitly documented in regulatory texts.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents mandate that emergency medical attention must be sought immediately in the event of a Cefixime overdose. This requirement is in place due to the potential for severe, documented complications.

Documented Overdose Manifestations

The clinical presentation of overdose primarily involves the gastrointestinal system, where high single doses may cause nausea, vomiting, and diarrhea. More serious, regulator-documented manifestations affect the Central Nervous System (CNS). These severe outcomes include the risk of seizures and signs associated with encephalopathy, such as confusion, impairment of consciousness, and movement disorders.

Official Emergency Actions and Constraints

Overdose management is explicitly described as symptomatic and supportive treatment. The official prescribing information states that no specific antidote is known for Cefixime. This profile influences the procedural constraints, as the drug is officially documented as not being removed in significant quantities by hemodialysis or peritoneal dialysis. A critical population-specific consideration noted in the regulatory labeling is that individuals with renal impairment carry an increased risk of developing severe CNS toxicity, including seizures and encephalopathy, if the standard dosage is not appropriately reduced.

Therapeutic Uses of Sofix

What Sofix Treats: Main Uses and Benefits

Sofix (Cefixime) is an oral third-generation cephalosporin antibiotic commonly used to help with acute bacterial infections across several key organ systems. The therapeutic benefit of this antibiotic may be applied in conditions where symptoms are driven by susceptible bacterial proliferation, contributing to easing the overall symptom load during symptomatic periods.

The medication is generally relevant in conditions characterized by periods of heightened symptoms, which may involve infections of the throat and tonsils (Pharyngitis and Tonsillitis), middle ear infection (Otitis Media), Uncomplicated Urinary Tract Infections (UTIs), and Acute Exacerbations of Chronic Bronchitis (AECB).

It helps address symptom clusters that may become intense or disruptive, such as fever, localized pain, and painful or frequent urination (dysuria). Using this medication supports patients during difficult episodes by easing distress and contributes to managing symptoms that interfere with daily comfort.

“Sofix is generally relevant when supportive symptom management is appropriate, particularly in community-acquired bacterial infections where symptoms interfere with daily functioning.”


Quick Fact: Management of Acute Discomfort

Quick Fact: Management of Acute Discomfort in the urogenital and respiratory tracts may be part of symptomatic management, especially in pediatric patients with conditions like otitis media.

Eligibility and Restrictions for Use

Sofix (Cefixime) is subject to strict population eligibility rules defined in official regulatory documents. Use is contraindicated in patients with a known allergy (hypersensitivity) to cephalosporin antibiotics or a history of a severe reaction to any other beta-lactam antibiotic, such as penicillin.

Age-Related Eligibility

Age Group Eligibility Status (Regulatory Wording)
Adults and Adolescents Established for use.
Children Established for use in patients six months of age or older (or weighing >45 kg).
Infants Safety and efficacy have not been established in infants less than six months of age, and use is not recommended.

Condition-Based Restrictions

Use of Sofix is conditional or restricted in certain populations:

  • Renal Impairment: The medicine may be used, but dose adjustment is required for adult patients whose creatinine clearance is le 60 mL/min. Use in children with renal insufficiency is not recommended due to insufficient data.
  • Pregnancy (Category B): Sofix should be used during pregnancy only if clearly needed.
  • Lactation: Consideration should be given to discontinuing nursing temporarily during treatment, as it is unknown whether Cefixime is excreted in human milk.
  • Other Comorbidities: Caution must be exercised when prescribing to patients with a history of gastrointestinal disease, particularly colitis, and to those with phenylketonuria (PKU) if using the chewable tablet form, which contains phenylalanine.

These limitations establish the profile for Sofix, defining who is absolutely excluded and which populations require regulatory-mandated caution or conditional use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Sofix (Cefixime) around two primary domains: Pharmacodynamic Coagulation Effects and Pharmacokinetic Exposure Modification. All documented interaction outcomes are based strictly on government-approved labeling.


Documented Pharmacodynamic and Exposure Interactions

Co-administration with Warfarin and other Coumarin-type anticoagulants is documented to result in a formal increase in prothrombin time (PT), which may be associated with clinical bleeding. An additive risk of additional renal impairment is officially noted when Cefixime is co-administered with other nephrotoxic drugs, such as Aminoglycosides and high-dose Loop Diuretics.

Interacting Substance Official Regulatory Outcome
Probenecid Increases Cefixime systemic exposure (Cmax and AUC) by decreasing its renal clearance.
Carbamazepine Elevated Carbamazepine plasma levels have been reported when taken concurrently.
Salicylates (approx 650 mg dose) Decreases Cefixime Cmax and AUC by 20-25%.

Administration and Test Interference

The absorption profile shows a pharmacokinetic interaction with food, where the time to maximal absorption (Tmax) is increased by approximately 0.8 hours, although overall absorption is generally not significantly modified. The regulatory label notes that Cefixime may reduce the efficacy of oral contraceptives.

Cefixime interferes with certain laboratory tests, potentially causing false-positive reactions for glucose in urine tests using Benedict’s, Fehling’s, or Clinitest solutions, and for the Coombs test.

Mechanism of Action

Sofix: Mechanism of Action

Sofix modulates specific biological signaling pathways. Its action is defined by key mechanistic domains that influence systemic physiological output by modifying signal transduction.

Regulation of Mediator-Dominant Systems

Sofix acts within systems where specific transmitters or mediators dominate, engaging mechanisms that regulate dysregulated processes. This action initiates or suppresses signaling sequences and reduces downstream consequences resulting from elevated mediator activity, altering signaling sequences to dampen heightened physiological output.

Targeted Pathway Adjustment and Modulation

The drug's mechanism involves receptor- or enzyme-mediated signaling, where it is used to modify pathway activity. By altering early molecular steps, Sofix induces changes in physiological parameters consistent with pathway modulation.

Influence on Feedback Regulation within Cascades

Sofix re-establishes internal feedback loops consistent with baseline pathway activity by engaging mechanisms that influence feedback regulation within pathways. This action is relevant in cascades where multiple layers of pathway activation occur.

Dosage and Administration Information

The official use of Sofix (Cefixime) is governed by specific instructions regarding administration, dosing, and duration as outlined in official pharmaceutical documentation.


Administration Route and Standard Dosing

Sofix is strictly for oral administration, available in tablets, capsules, chewable tablets, and oral suspension. For adults and adolescents over 12 years of age (or weighing more than 45 kg), the recommended daily dose is 400 mg. This dose may be taken once daily or split into two equal doses of 200 mg every 12 hours. The official instructions state that the capsule and standard tablet forms may be taken without regard to food.

However, form-specific rules apply: chewable tablets must be chewed or crushed before swallowing, and the oral suspension requires shaking well before each measured dose. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose, in which case the missed dose should be skipped; no dose should be doubled.


Population Rules and Course Duration

Dosing for pediatric patients aged 6 months and older is weight-based, with a recommended total daily dose of 8 mg/kg/day of the suspension, which may also be divided. Adults with marked renal impairment (Creatinine Clearance <60 mL/min) require a specific reduction of the total daily dose to prevent accumulation. A key procedural rule for proper use is the course duration: for infections caused by Streptococcus pyogenes, administration must be maintained for a minimum of 10 days. Furthermore, the official documents state that the standard tablet or capsule is not interchangeable with the chewable tablet or oral suspension when treating otitis media.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sofix (Cefixime)

The body of research for Sofix (Cefixime) includes clinical trials, such as randomized controlled trials (RCTs), and scientific reviews. These studies, which underpin regulatory context, describe the patterns of bacterial clearance and how outcomes related to physical discomfort were measured in the observed populations. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.


Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs)

Research exploring short-term symptom changes has widely evaluated Sofix for uncomplicated urinary tract infections, which are conditions characterized by acute or disruptive episodes. Studies, often conducted as short-term RCTs with non-pregnant adult women, examined two main outcomes: the eradication of the causative bacteria (bacteriological clearance) and measures of clinical change related to the patient-reported outcomes describing perceived discomfort.

Studies conducted during periods of increased symptom activity monitored measurements of both the bacterial clearance rates and the proportions of participants who described patterns of symptom change in the short term. The study results reflect the specific conditions under which they were conducted. Comparative evidence is lacking for certain specific patient subgroups, and findings are uncertain when evaluating the use of Sofix against less common or highly resistant bacterial strains.

Evidence for Use in Acute Otitis Media and Pharyngitis/Tonsillitis

Research examined Sofix in two related conditions: Otitis Media (middle ear infection) and Pharyngitis/Tonsillitis (throat infection). For Otitis Media, comparative clinical trials, often using the liquid suspension formulation, were conducted in pediatric patients (children 6 months and older). Research explored short-term symptom changes, monitoring outcomes related to physical discomfort alongside the goal of achieving bacteriological clearance.

For Pharyngitis and Tonsillitis caused by S. pyogenes, research explored outcomes related to systemic or functional imbalance, monitoring bacteriological eradication and short-term clinical change. Regulatory reports highlight that while these studies suggest patterns related to bacterial clearance, evidence establishing the prevention of late, severe complications is not available from Cefixime-specific research. Therefore, certainty remains low regarding this long-term public health outcome.

What Remains Unclear: Research Gaps and Uncertainty

Most key clinical trials for Sofix were designed to observe responses over defined time intervals, meaning follow-up durations were typically limited to the short term. Long-term effects are not fully established or consistently characterized across the evidence landscape. The primary limitation noted across regulatory assessments is that long-term effects are not fully established regarding the durability of findings and the risk of recurrence or relapse over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Sofix (FAQ)


Q: Is Sofix approved by the FDA?

A: Yes, Sofix (Cefixime) is a prescription-only medicine that has been approved by the U.S. Food and Drug Administration (FDA) and is also approved by other international regulatory authorities.


Q: Is Sofix available as a generic medicine?

A: Yes, Sofix is the trade name for the active ingredient Cefixime. Regulatory bodies have approved Cefixime as a generic medicine and it is available in various approved generic formulations.


Q: Why are there different strengths of Sofix available?

A: Different strengths are available to allow for flexible dosing. This is necessary to accommodate various patient groups, including specific weight-based pediatric dosing and the option for split adult dosing.


Q: Is Sofix used for any conditions other than the main one listed?

A: Yes, in addition to common uses like urinary tract and ear infections, regulatory documents also indicate Sofix for treating certain other bacterial conditions. These include acute exacerbations of chronic bronchitis and uncomplicated gonorrhea.


Q: Can Sofix be crushed or split?

A: The administration instructions for Sofix vary by formulation. The official guidance specifies that chewable tablets must be chewed or crushed before swallowing. The product information for the standard tablet or capsule does not include instructions for splitting or crushing.


Q: How quickly does Sofix leave the body?

A: According to the official product information, the rate at which Sofix is cleared from the bloodstream is measured by its serum elimination half-life. For adults with normal kidney function, this half-life typically ranges from 2.4 to 4 hours.


Q: What happens if a person stops taking Sofix suddenly?

A: Regulatory information indicates that incomplete courses, even when symptoms improve, are associated with a potential return of the original infection and may increase the risk of developing drug-resistant bacteria. The full prescribed amount of the medicine is required to address the infection.


Q: Why do some people need to take Sofix for a long time?

A: The full course of treatment is required to address the infection. For infections caused by Streptococcus pyogenes, official documents establish a minimum administration period of 10 days.


Q: Does Sofix need to be stored in the refrigerator?

A: Storage instructions depend on the formulation. The solid forms (tablets and capsules) are generally stored at controlled room temperature. However, the reconstituted oral suspension may require storage in the refrigerator and has a limited use period.


Q: Can people with kidney issues use Sofix?

A: Use of the medicine is conditional for patients with kidney issues (renal impairment). A specific dose adjustment is required for adult patients with moderate to severe kidney impairment. Use is not recommended for children with kidney insufficiency due to insufficient safety data.


Q: Is Sofix appropriate for older adults (seniors)?

A: Use is established for the general adult population, including older adults. Regulatory information does not list a specific contraindication or special requirement for seniors that is different from other adult patients.


Q: Is Sofix okay to use while breastfeeding, according to official sources?

A: Due to the lack of established data on whether the active ingredient, Cefixime, is excreted in human milk, official documents state that the regulatory position requires consideration of temporary discontinuation of nursing during treatment.


Q: Is it safe to drink alcohol in moderation while on Sofix?

A: The official regulatory documents for Sofix do not list a specific drug-alcohol interaction or prohibition. If a patient chooses to consume alcohol, official guidance supports discussion with a healthcare professional before or during treatment.


Q: Can I take Sofix if I also take a vitamin supplement?

A: Official regulatory documents do not list specific interactions with common vitamin supplements. However, official guidance notes the importance of informing a healthcare professional about all supplements, including vitamins and herbal products.


Q: Is it true that Sofix can interact with herbal products?

A: The official interaction profile does not list specific interactions with common herbal products. Official guidance supports informing a healthcare provider about all supplements, including herbal products, as part of assessing treatment suitability.


Q: Does Sofix interact with common over-the-counter pain medications?

A: Official drug documents note a specific interaction with Salicylates, which are found in certain over-the-counter pain relievers. This interaction indicates that certain doses of Salicylates may decrease the total exposure of Sofix in the body by 20 to 25 percent.


Q: Is Sofix known to cause stomach upset?

A: Gastrointestinal issues are among the most frequently reported adverse reactions listed in the official safety profile. These include diarrhea, loose stools, abdominal pain, and nausea.


Q: How common is it to experience a headache with Sofix?

A: Headache is a documented adverse reaction to Sofix. In official documents, it is classified as Uncommon or Less Common, meaning it is not among the most frequently observed side effects.


Q: Do most people who take Sofix experience weight gain?

A: Weight gain is not listed as a common or frequently reported adverse reaction in the official regulatory documentation for Sofix.


Q: Can Sofix cause sleep problems?

A: Sleep problems are not listed among the commonly reported Nervous System side effects in the regulatory documents, which list effects such as headache and dizziness.


Q: Can Sofix cause problems with vision?

A: Vision problems are not listed among the commonly reported or frequently documented side effects in the official regulatory documentation for Sofix.


Q: Is Sofix known to cause dry mouth, and is that a common side effect?

A: Dry mouth is not listed among the commonly or frequently reported adverse reactions in the official regulatory documentation.


Q: What should a patient do if they experience unusual symptoms while on Sofix?

A: Official regulatory information includes a general statement that patients experiencing symptoms that worsen, persist, or are serious or unusual should seek guidance from a healthcare professional or pharmacist.


Q: What does the research say about the long-term effects of Sofix?

A: Regulatory reviews indicate that most key clinical trials observed responses over defined short-term intervals. Therefore, the long-term effects of Sofix are not fully established or consistently characterized across the current body of evidence.

How should Sofix be stored and disposed of?

Storage Requirements for Sofix

Sofix (Cefixime) solid dosage forms (tablets and capsules) must be stored at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container, which should be tightly closed to protect it from heat and moisture. It is required to store this medication out of the reach of children.

Stability and Disposal

The reconstituted oral suspension has a limited stability and must be discarded after 14 days, regardless of whether it is stored at room temperature or refrigerated. The suspension must not be allowed to freeze. Unused or expired Sofix should be disposed of by following specific guidance, such as using a drug take-back program. The liquid formulation must not be poured down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sofix found in:

A-Z Index: